ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 174 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2019. The put-call ratio across all filers is 0.88 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,505,574 | +58.1% | 1,536,300 | +124.3% | 0.00% | +100.0% |
Q2 2023 | $952,194 | -30.1% | 685,032 | -20.1% | 0.00% | -50.0% |
Q1 2023 | $1,362,948 | -84.6% | 857,200 | -39.5% | 0.00% | -84.0% |
Q4 2022 | $8,821,680 | +21.4% | 1,416,000 | +30.6% | 0.02% | +19.0% |
Q3 2022 | $7,265,000 | +8447.1% | 1,084,300 | +7991.8% | 0.02% | – |
Q2 2022 | $85,000 | -96.0% | 13,400 | -77.1% | 0.00% | -100.0% |
Q3 2019 | $2,141,000 | -70.1% | 58,400 | -62.0% | 0.01% | -72.2% |
Q2 2019 | $7,155,000 | +164.0% | 153,800 | +127.9% | 0.02% | +157.1% |
Q1 2019 | $2,710,000 | +26.2% | 67,500 | +44.5% | 0.01% | +16.7% |
Q4 2018 | $2,148,000 | +39.4% | 46,700 | +119.2% | 0.01% | +50.0% |
Q1 2018 | $1,541,000 | -2.5% | 21,300 | -11.2% | 0.00% | 0.0% |
Q4 2017 | $1,580,000 | +112.9% | 24,000 | +62.2% | 0.00% | +100.0% |
Q3 2017 | $742,000 | -85.8% | 14,800 | -76.8% | 0.00% | -95.0% |
Q2 2015 | $5,213,000 | +151.8% | 63,759 | +185.2% | 0.04% | +150.0% |
Q1 2015 | $2,070,000 | – | 22,359 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |